Stocktwits on MSN
ALT stock rallies 4% — what does retail think?
The BTD designation was granted on the basis of data from a mid-stage trial in which pemvidutide demonstrated statistically ...
Altimmune, Inc.’s Pemvidutide shows promise as a dual-action treatment for obesity and MASLD/MASH, targeting weight loss, liver health, and cardiovascular support. Their Phase 2 MOMENTUM trial for ...
Zacks Investment Research on MSN
ALT stock up 17% after pemvidutide gets FDA breakthrough tag for MASH
Altimmune ALT announced that the FDA has granted Breakthrough Therapy Designation to its lead pipeline candidate, pemvidutide, a novel, investigational GLP-1/glucagon dual receptor agonist, for the ...
On Thursday, Altimmune, Inc. (NASDAQ:ALT) released topline results from the IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH). Treatment discontinuation ...
GAITHERSBURG, Md., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (ALT) (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results